BRCA1 and breast carcinoma: First, the low incidence of BRCA1/2 mutations in breast cancer leads to limited access to PARPis; second, breast cancer cells, particularly TNBC cells, have been observed to rapidly develop resistance to PARPis through multiple pathways after treatment14.